Session:	Treatment Strategies for Multiple Sclerosis
	Capsule: Many issues regarding when and how to start treatment and what are the future avenues are not clear!
	Debate: Clinically isolated syndromes (CIS): to treat or not to treat To treat: G. Comi, Italy Not to treat: A. Siva, Turkey
	Stem cells in multiple sclerosis: actuality vs. potentiality G. Martino, Italy

Session:	Multiple sclerosis (MS) – Switching Between Treatments
	Capsule: When and based on what should we switch between treatments in MS patients?
	Role of Clinical and MRI parameters TBA
	Role of Biomarkers K. Selmaj, Poland
	New players: The Natalizumab/Tysabri experience / FTY 720 P. Hartung, Germany

Stroke
Session:	tPA in Stroke
	Capsule: tPA makes an important contribution to stroke therapy, but only a few benefit. How can we extend the value?
	Intra-arterial tPA TBA
	Debate: Is tPA the treatment of choice in acute ischemic stroke? TBA

Session:	Interventions in Stroke Prevention
	Debate: Carotid endarterectomy is better than carotid stenting Yes: J. Wojczal, Poland No: N. Bornstein, Israel

Session:	Debate: Stereotactic Radiosurgery in Neurofibromatosis Type 2 (NF2)
	Capsule: The relative benefits of radiosurgery and conventional operations is not yet clear
	Pro radiosurgery: J. Rowe, UK Pro operation: G. Evans, UK

Dementia
Session:	Mild Cognitive Impairment
	Capsule: Dementia typically develops insidiously. An intermediate stage between normal aging and dementia termed mild cognitive impairment (MCI) is still not well understood nor generally accepted.
	Debate: Is Mild Cognitive Impairment a useful concept? Yes: S. Gauthier, Canada No: J. Morris, USA
Session:	A Cure for AD
	Capsule: Because beta-amyloid is a hallmark of Alzheimer disease, attempts are being made to eliminate this protein. One of the new methods to achieve this is through anti-amyloid immunization, while a competitive method is by inhibition of APP-cleaving enzymes.
	Debate: Immunization will cure AD Yes: TBA No: E. Giacobini, Switzerland
Session:	Autoimmune Dementia
	Capsule: In addition to the common causes of dementia, some patients are thought to have an underlying autoimmune mechanism. When should these be considered and how should they be treated?
	Hashimoto (dysthyroid) encephalopathy A. Chaudhuri, UK
	Potassium channel antibody encephalopathy A. Vincent, UK
	Anticardiolipin antibodies J. Chapman, Israel

Session:	Treatment of Cognitive Impairment
	Capsule: Cholinesterase inhibitors (ChEI's) and memantine are the only approved drugs for the treatment of Alzheimer’s disease (AD), but there is debate on their efficacy, both in early and (even more) in advanced AD.
	Debate:  Treatment of dementia with ChEI’s is appropriate Yes: B. Winblad, Sweden No: TBA
	BACE inhibition is the solution H. Fillit, USA
	Gamma secretase modulation TBA

Session:	Incipient Dementia
	Capsule: Several studies demonstrate that education and involvement in intellectually demanding activities protect against dementia.
	Debate: Cognitive training is a valuable tool for older people with memory impairment Pro: E. Shatil, Israel Cons: TBA
	Debate: Treatment of MCI is available and should be given Yes: L. Spiru, Romania No: P.J. Visser, The Netherlands
Session:	Debate: Vascular Cognitive Impairment is a Misleading Concept
	Capsule: Dementia or milder forms of cognitive decline can occure following obvious strokes or in conjunction with vascular risk factors. Recently the term vascular cognitive impairment has been suggested to encompass vascular dementia, Biswanger’s disease and multi-infarct dementia. However, this term has not been unchallenged.
	Yes: A. Kertesz, Canada
	No: V. Hachinski, Canada

Neuroprotection and neuroplasticity
Session:	Neuroprotection and Neuroplasticity
	Blood-brain barrier and neuroprotection H.S. Shanker, Sweden
	Vascular protection in stroke O. Bajenaru, Romania
	Neuroprotection in acute ichemic stroke-Is there still hope? N. Bornstein, Israel
	Neuroprotection - An innovative approach L. Csiba, Hungary
	Neuroprotection and neuroplasticity - a dualistic vision of a continuous process D. Muresanu, Romania

Parkinson
Session:	Pathogenesis of PD
	Capsule: In spite of much research, the pathogenesis of PD is still contested. Is there one cause that can be thought of as initiating the cascade?
	PD is a mitochondrial dysfunction disease T. Schapira, UK
	PD is due to synuclein dysfunction W. Olanow, USA
	Is PD a ferrinopathy? D. Berg & J. Godau, Germany
	Olfactory dysfunction in early PD suggests that the disease is caused by a toxin H. Reichmann, Germany
Session:	Early PD
	Capsule: Continuous dopaminergic stimulation in early PD may best prevent the development of motor complications
	Are resagiline and selegiline neuroprotective? M. Youdim, Israel
	Is continuous dopaminergic therapy really important in the initial stages of PD? F. Stocchi, Italy
	Dopamine agonists are the treatment of choice in early PD M. Guttman, Canada
Session:	Parkinson’s Disease: Motor Aspects
	Capsule: How can we control the motor complications in PD?
	DBS vs apomorphine infusions in complicated PD TBA
	Is DBS ready for early PD? A. Kupsch, Germany
	Spheramine–cell therapy for Parkinson’s disease E. Reissig, Germany

Session:	Parkinson’s Disease: Non-Motor Aspects
	Capsule: Non dopaminergic symptoms may be more relevant than DA-responsive motor symptoms in PD
	The treatment of depression in PD patients TBA
	Is dementia inevitable in PD? I. Litvan, USA
	Compulsive behaviour is the most significant adverse event due to dopaminergics N. Giladi, Israel
	Daytime somnolence in PD – How to avoid and how to treat? K.R. Chaudhuri, UK
Session:	Parkinsonian Syndromes
	Capsule: Movement disorders with Parkinsonian features have been diagnosed using different methods, using different criteria, but the basic question remains of the nosologic entities underlying these neurodegenerative diseases.
	Debate: Are PSP and CBGD the same disease? For: A. Kertesz, Canada Against: I. Litvan, USA
	SPECT imaging in the differential diagnosis of Parkinsonian syndromes TBA

Epilepsy
Session:	Epilepsy
	Patients with epilepsy who are unresponsive to drugs should be considered for surgery and the identification of suitable cases usually involves expensive videotaping and seizure monitoring.
	Debate: Is videotaping always necessary for decision on surgery in epilepsy? Yes: H. Stefan, Germany No: M. Sperling, USA
	The success rate of a third antiepileptic drug is so low that it is unjustified to delay surgery S. Benbadis, USA
Session:	Psychogenic Neurological Disorders
	Capsule: Clinicians are still facing frequent difficulties in differentiating “organic” from “functional”  disorders
	Is psychogenic dystonia a valid diagnosis? K. Black, USA
	Vertigo as a psychogenic disorder M. Strupp, Germany
	Is Regional Sympathetic Dystrophy (RSD)–dystonia an organic disease? M. Hallett, USA
	Psychogenic non-epileptic seizures – can they be diagnosed by any neurologist? Can they be treated by neurologists?  C. Elger, Germany
Session:	Autoimmune Disorders
	Capsule: The pathogenesis of “antibody-negative” myasthenia is still unclear. What is the role of antibodies against non-cholinergic targets? The role of thymectomy in the treatment of myasthenia is also still controversial.
	The autoimmune spectrum of myasthenia A. Vincent, UK
	CIDP TBA

Session:	Treatment of Migraine: Beyond Triptans
	Capsule: Therapy of chronic headache frequently unsatisfactory and newer methods for symptomatic therapy are needed. Botulinum toxin injections are such methods, which have still not received wide acceptance.
	Debate: Botulinum toxin in the treatment of headache Proposition: Botox is effective for headache TBA Opposition: Botox should be used cautiously, due to its risk TBA